CRISPR Therapeutics has reported strong commercial progress for its gene therapy CASGEVY, with patient initiations nearly tripling year over year. The company plans to submit a regulatory application in the first half of 2026 to expand CASGEVY's approval to paediatric patients. The company's cardiovascular candidate CTX310 showed positive early clinical data, published in the New England Journal of Medicine, and is advancing into Phase 1b trials. CASGEVY is already commercially available, marking the company's transition from development to approved therapy. Despite the clinical progress, CRISPR Therapeutics remains unprofitable with a net loss of $581.6 million and limited revenue of approximately $3.5 million. The share price trades around 44% below analyst consensus targets, reflecting ongoing execution risk around trials and regulatory approvals.

CRISPR Therapeutics reported $116 million in revenue for fiscal year 2025, driven by its gene-editing therapy CASGEVY. The company generated $54 million in Q4 alone, with patient initiations increasing nearly threefold year-on-year. To date, 147 patients have begun treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe and the Middle East. The company is advancing its in vivo liver editing portfolio, including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials mid-2026. CRISPR is also collaborating with Sirius Therapeutics on thromboembolic disease treatments, with Phase 2 data for its lead Factor XI candidate anticipated in the second half of 2026.

CRISPR Therapeutics has announced a $350 million offering of convertible senior notes to fund general corporate purposes, including pipeline development and commercialisation efforts. The gene editing therapy company currently trades at $52.80, approximately 38% below analysts' consensus target of $84.78. The convertible debt offering provides capital without immediate equity dilution, though conversion terms could affect the company's current 96 million share count. CRISPR Therapeutics generated only $4 million in revenue whilst posting ongoing losses, raising concerns about potential future dilution if pipeline development does not progress as planned. The company's shares have shown recent momentum with an 8.3% gain over 30 days. According to Simply Wall St's valuation model, shares trade 72.2% below estimated fair value.